As investors crowd into AI names at record highs, these three healthcare stocks offer more compelling valuations.Healthcare stocks have struggled since interest rates began climbing in 2022. Rising yields pulled capital away from speculative biotech and drug development, pushing valuations lower even as research pipelines advanced. Many promising companies now trade at a fraction of their previous highs, while investors pour money into artificial intelligence (AI) names trading at record multiples.That gap ...

Intellia Therapeutics, Inc. (NTLA) shares ended the last trading session 19.7% higher at $24.47. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 72.1% gain over the past four weeks.The price rise can be attributed to growing investor optimism related to the company’s leading in vivo genome-editing candidates, nex-z and lonvo-z, which are being developed for treating transthyretin (ATTR) amyloidosis and hereditary a ...

We recently published 10 Big Names With Explosive Growth. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is one of the best performers on Wednesday. Intellia rallied to a new all-time high on Wednesday, as investors took path from two investment firms’ “buy” recommendations for its stock. During the session, Intellia Therapeutics, Inc. (NASDAQ:NTLA) soared to an all-time high of $26.46 before paring gains to end the day just up by 19.72 percent at $24.47 apiece. Intellia Therapeutics (NTLA) Soars to New High ...

Intellia Therapeutics, Inc. (NTLA) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Since a chan ...

Intellia Therapeutics, Inc. (NTLA) closed the last trading session at $20.44, gaining 72.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $33.46 indicates a 63.7% upside potential.The mean estimate comprises 24 short-term price targets with a standard deviation of $24.02. While the lowest estimate of $8.00 indicates a 60.9% decline from the current price level, the most optimisti ...

Intellia is collaborating with Regeneron Pharmaceuticals , a leading biotech company, to develop nex-z. This therapy targets transthyretin (ATTR) amyloidosis, a disease caused by the buildup of abnormal transthyretin proteins in the heart, which can lead to heart problems or other issues. ATTR amyloidosis can either be hereditary or acquired with age. Intellia is conducting a phase 3 study for nex-z in ATTR amyloidosis with cardiomyopathy (a condition in which the heart has difficulty pumping blood), as wel ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

The ongoing US government shutdown, expectations of additional Fed easing, and political uncertainty in France and Japan are also driving investors to haven assets, such as gold and Bitcoin. French Prime Minister Lecornu resigned after President Macron named a new cabinet, raising uncertainty about the Eurozone's second-largest economy. Meanwhile, Sanae Takaichi, a proponent of easy fiscal and monetary policy, won Saturday's election to become Japan's new leader of the ruling LDP party and potential prime m ...

Key Takeaways Amneal Pharmaceuticals stock jumped 29.9% since its Zacks Rank upgrade on July 25.Leidos shares have advanced 19.8% after a similar Zacks Rank upgrade on July 28.Vishay Precision rose 21.5% following a Zacks Recommendation upgrade to Outperform.Last week, the U.S. stock market delivered a strong performance, with all major indices, including the S&P 500, the tech-heavy Nasdaq Composite and the Dow Jones Industrial Average, advancing by 0.82%, 0.84%, and 0.96%, respectively. Amid a partial gove ...

CAMBRIDGE, Mass., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that on October 1, 2025, it awarded inducement grants to six new employees under Intellia’s 2024 Inducement Plan as a material inducement to employment. The inducement grants consisted of time-based restricted stock units (“RSUs”) for an aggregate of 65,200 shares of Intellia’s common stoc ...